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Summary 
The ability of ketamine, phencyclidine and analogues to alter 
catecholamine secretion from cultured bovine adrenal chromaffin 
cells was investigated. Both ketamine and phencyclidine 
specifically inhibited nicotinic agonist-induced secretion at 
concentrations which did not alter secretion induced by elevated + 
K depolarization. The inhibition of nicotinic agonist-induced 
secretion was not overcome by increasing concentrations of nico- 
tinic agonist. The effects of stereoisomer pairs of 
phencyclidine-like drugs - dexoxadrol, levoxadrol and (+)PCMP, 
(-)PCMP - did not reveal stereospecificity for the inhibition, in 
contrast to the stereospecific behavioral effects of the drugs. 
The local anesthetic lidocaine (0.3 mM) also noncompetitively 
inhibited nicotinic agonist-induced secretion without inhibiting 
elevated K+-induced secretion. The data indicate that ketamine 
and phencyclidine at clinically relevant concentrations 
specifically inhibit the adrenal chromaffin cell nicotinic receptor 
at a site similar to or identical with the site of action of local 
anesthetic. Although the nicotinic receptor inhibition is probably 
not related to the anesthetic and behavioral effects of ketamine 
and phencyclidine, it is likely that the centrally mediated 
increase in sympathetic nervous system activity which is 
characteristic of these drugs is moderated by the peripheral 
blocking effects on catecholamine secretion from the adrenal 
medulla. 
Ketamine is a widely used intravenous general anesthetic with significant 
behavioral side effects (I). The related compound phencyclidine is also a 
general anesthetic but is not used clinically because of its more intense 
behavioral effect which produces a schizophrenia-like syndrome in man (2). 
Phencyclidine ("Angel Dust") is a widely used drug of abuse and its pharma- 
cology is of great clinical importance. These compounds alter the function of 
various ionic channels in excitable tissue and inhibit the function of nico- 
tinic receptors on skeletal muscle (3). We have investigated the effects of 
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ketamine, phencyclidine and analogues on catecholamine secretion from cultured 
bovine adrenal chromaffin cells. We found that the drugs specifically and 
noncompetitively inhibited secretion induced by nicotinic agonists in a manner 
similar to the inhibition caused by the local anesthetic lidocaine. The 
concentrations of drugs which inhibit secretion from chromaffin cells indicate 
that clinically the drugs may inhibit the physiological response of the adrenal 
medulla. While this work was in progress, Malave et al. reported that 
phencyclidine inhibited acetylcholine-induced secretion from perfused bovine 
adrenal glands (4). 
Materials and Methods 
Cells disaggregated from bovine adrenal medullae were added to 16 mm 
diameter uncoated culture wells (Costar, Cambridge, Mass.) at a density of 
500,000 cells/well in 1 ml of Eagle's MEM (GIBCO, Grand Island, N.Y.) supple- 
mented with 10% heat-inactivated fetal calf serum (GIBCO), i0 ~M cytosine 
arabinoside (to inhibit fibroblast proliferation), gentamycin (50 Hg/ml), and 
Fungizone (2.5 ~g/ml) (Squibb, Princeton, N.J.) (5). After 4 days at 34 ° in 5% 
CO2/95% air the chromaffin cells had formed monolayers which contained 
approximately 20 nmoles catecholamine per well. The incubation medium was 
replaced after 4 days and experiments were performed on days 5-10. Medium was 
replaced with cytosine arabinoside-free medium 24 hours before an experiment. 
Experiments were performed at 25 ° in physiological salt solution containing 145 
mM NaCI, 5.6 mM KCI, 2.2 mM CaCI2, 0.5 mM MgCI , 5.6 mM glucose, 15 mM 
4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid 2 (pH 7.4), and 0.5 mM 
ascorbic acid. In most experiments, 0.5% bovine serum albumin was also + 
present. Elevated K PSS contained 56.0 mM KCI and 95.0 mM NaCI. The 
release of endogenous catecholamine was measured using a fluorescent assay as 
previously described (5). Secretion was measured after 15 minutes in the 
presence or absence of various drugs. Secretion is expressed as the fraction 
of the total catecholamine released into the medium and the data presented as 
mean ± standard error of the mean. Standard error of the mean bars smaller 
than the point symbols were omitted from figures. Statistical significance was 
evaluated with Student's 't' test. Ketamine, phencyclidine and analogues were 
kindly provided by Dr. James Woods, Department of Pharmacology, University of 
Michigan Medical School. 
Results 
Effects of phencyclidine and ketamine on secretion. Both phencyclidine 
and ketamine caused a dose-dependent inhibition of secretion stimulated by the 
nicotinic agonist DMPP (Figure I). The inhibition of both compounds was 
virtually complete at the highest concentrations investigated. Phencyclidine 
was approximately 7 times more potent than ketamine. 
Although phencyclidine was a potent inhibitor of nicotinic agonist-induced 
secretion, +it had no effect on secretion induced2bY depolarization wi~ 
elevated K -containing solution (Figure 2) or by Ba substitution for Ca 
for 12 minutes (data not shown). Similar results were obtained with ketamine 
• . + 
(data not shown). Secretlon induced by elevated K is probably initiated by 
z+ 
Ca entering through voltage sensitive Ca channels and does not involve the 
nicotinic receptor (5). Secretion induced by Ba z+ also does not involve 
stimulation of the nicotinic receptor. The data, therefore, indicate that both 
phencyclidine and ketamine block secretion by specifically inhibiting the 
nicotinic receptor-channel complex and not by inhibiting events within the cell 
after nicotinic receptor-channel activation. 
Characterization of inhibition, reversibility, and stereospecificity. The 
ability of increasing concentrations of DMPP to overcome the phencyclidine- 
Vol. 35, No. 18, 1984 Ketamine and Catecholamine Secretion 1853 
,oo- ~ - ~ ~  FIG. ] 
~p ~ __ K~TA~ Ketamine and phencyclidine inhibitiom 
of nicotinic agonist-induced 
catecholamine secretion. Chromaffin 
cells were incubated in the presence or 
absence of the nicotinic agoni~t DMPP 
so- (I0 L,M) together with various concen- 
tlations of either phencyclidine (PCP) 
\ or ketamipe. After ]5 minutes, the 
~ amount of DMPP-induced secretion was 
determined. There were 4 wells/group. 
2~- DMPP-induced secretion in the absence 
of inhibitor was 25% of the tota] 
catecholamine and corre:~ponds to i00 in 
0 0 | N I I I i I the figure. Basal release in the 
t0-' I0-' I0-' ~0-' 10- absence of DMPP was 3% and wc~s 
[i,,imto,]M unaltered by phencyc]idine or ketamine. 
FIG. 2 
s0- Effects of phencyclidine on DMPP- 
induced and elevated K+-induced 
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cells were incubated in the presence or 
absence of DMPP (I0 HM) or elevated 
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induced inhibition of secretion was investigated (Figure 3). The blockade of 
secretion by a moderate concentration of phencyclidine was not surmountable by 
increased concentrations of DMPP. These data suggest that phencyclidine was 
not competing with DMPP at the receptor binding site. However, the effect of 
phencyclidine was reversible. Incubation of cells with I0 ~M phencyclidine for 
I0 minutes followed by a i0 minute incubation in phencyclidine-free solution 
resulted in subsequent DMPP-induced secretion that was within 90% of DMPP- 
induced secretion from cells not incubated with phencyclidine. 
30- 
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FIG. 3 
The effects of phencyclidine on the concentration dependency of 
DMPP-stimulated secretion. Chromaffin cells were incubated in 
varying concentrations of DMPP in the presence or absence of 
phencyclidine (PCP), 4 ~iM). Secretion was determined after 15 
minutes. There were 4 wells/group. 
The ICs0'S for 2 pairs of stereoisomers of phencyclidine-like compounds 
- dexoxadrol, levoxadrol, and (+)PCMP, (-)PCMP - were investigated (Table I). 
There was little difference in the potency in either pair of stereoisomers. 
Effects of the local anesthetic lidocaine on catecholamine secretion. 
Local anesthetics are thought to inhibit the nicotinic receptor-channel complex 
by blocking ion flux through the channel and not by interfering with the 
agonist binding sites (6). The effects of the local anesthetic lidocaine on 
secretion from chromaffin were compared to those of phencyclidine. Lidocaine 
(0.3 mM) inhibited DMPP (I0 uM)-induced catecholamine secretion 70% but did not 
+ F 2+ inhibit elevated K -induced secretion ( igure 4A) or Ba -induced secretion 
(data not shown). The data are consistent with the selective inhibition by the 
local anesthetic tetracaine of acetylcholine-induced catecholamine secretion 
from suspended chromaffin cells (7). The blockade induced by lidocaine was not 
surmountable by increasing concentrations of DMPP (Figure 4B). Thus, both 
phencyclidine and lidocaine inhibit secretion by interacting with the nicotinic 
receptor-channel complex at a site that is probably different from the site of 
interaction of nicotinic agonists. 
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TABLE 1 




Phencyclidine 3 x 10_5 
Ketamine 2 x i0 6 
Dexoxadrol 6 x 10- 6 
Levoxadrol 4 x 10- 
(+)PCMP 3 x 10 -6 
(-)PCMP 4 x 10 -6 
The ability of various concentrations of the above drugs to inhibit 
DMPP (i0 ~M)-induced secretion during a 15 minute incubation was 
determined. The IC50's were estimated graphically and correspond 
to that concentra£1ons of drug which inhibfted DMPP-induced 
secretion 50%. 
2 0 ]  A - ' ~  ~ 30- 
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FIG. 4 
Effects of lidocaine on catecholamine secretion. A) Catecholamine 
secretion stimulated by DMPP (I0 ~M) or elevated K + (56 mM) was 
determined after a 15 minute incubation in the presence or absence 
of lidocaine (Lid., 0.3 mM). B) Catecholamine secretion was 
determined after 15 minutes in various concentrations of DMPP in 
the presence or absence of lidocaine (0.2 mM). There were 4 
samples/group, p <0.001 vs. no drug. 
Discussion 
Sites of action of ketamine, phencyclidine, and lidocaine. The general 
anesthetics and behaviorally active drugs ketamine and phencyclidine and the 
local anesthetic lidocaine inhibited nicotinic agonist-induced but not elevated 
K+-induced catecholamine secretion from adrenal chromaffin cells. The 
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inhibition by phencyclidine and lidocaine was not overcome by increased 
concentrations of nicotinic agonist. The data indicate that phencyclidine and 
ketamine inhibited secretion from bovine adrenal chromaffin cells by 
interaction with the nicotinic receptor-channel complex at a site that is 
probably different from the site of interaction of nicotinic agonist. The site 
may be similar to or identical with the site of interaction of lidocaine. 
Electrophysiological studies at the frog neuromuscular junction also 
demonstrated noncompetitive inhibition by phencyclidine of nicotinic 
stimulation (3). Binding of phencyclidine to the nicotinic receptor-channel 
complex of membranes from Torpedo marmorata indicates that there is a highly 
specific site of interaction which is probably not identical to the receptor 
binding site (8). Similar noncompetitive inhibition is caused by cholinergic 
antagonists such as hexamethonium, decamethonium, and histrionicotoxin on 
bovine adrenal chromaffin cells (9), on autonomic ganglion cells (i0), and at 
the neuromuscular junction (11,12). 
Studies on perfused bovine adrenal medulla resulted in similar but not 
identical findings to those in the present study. In perfused adrenal medulla 
phencyclidine (3 uM) inhibited acetylcholine-induced catecholamine secretion 
and caused little inhibition of the initial rat~ of Ba2+-induced secretion. 
However, phencyclidine significantly inhibited Ba2+-induced secretion after 3 + 
minutes (4). Lidocaine which had little or no effect on elevated K or 
BaZ+-induced secretion in the present study (0.2 mM lidocaine), enhanced 
Ba2+-induced secretion from perfused bovine adrenal glands (0.I mM lidocaine, 
13). It is possible that cultured chromaffin cells have somewhat different 
pharmacological characteristics from chromaffin cells in perfused glands. 
However it is also possible that phencyclidine and lidocaine in combination 5+ 
with Ba alter catecholamine release into the perfusate because of indirect 
actions. For example, changes in the perfusion of the gland caused by changes 
in the vasculature ~ay have been responsible for the effects of phencyclidine 
and lidocaine on BaZ+-induced secretion. 
Relationship of inhibition of secretion from chromaffin cells by 
phencyclidine and ketamine to behavioral and clinical effects. The inhibition 
of DMPP-induced catecholamine secretion from chromaffin cells was not sensitive 
to differences in stereoisomers of phencyclcidine-like drugs dexoxadrol, 
levoxadrol, and (+)PCMP (-)PCMP. In behavioral experiments dexoxadrol is much 
more potent than levoxadrol (14) and has a 40-fold greater affinity for CNS 
receptors (15). (+)PCMP is 5-6 fold more potent that (-)PCMP in causing 
phencyclidine-like CNS effects (16). Therefore, the effects of phencyclidine 
on the nicotinic receptor-channel complex of bovine adrenal chromaffin cells 
are probably unrelated to interactions in the central nervous system which are 
responsible for the behavioral effects of phencyclidine. The effects of 
phencyclidine on activation of nicotinic receptors at the neuromuscular 
junction are also unrelated to the behavioral effects of phencyclidine (3). 
There is recent evidence that the behavioral effects of phencyclidine are 
correlated to the inhibition of a particular class of K + channels (17). 
Inhibition of nicotinic agonist-induced secretion from chromaffin cells by 
ketamine (IC50 = 20 uM) and by phencyclidine (IC50 = 3 ~M) may be of 
clinical importance in ketamine-induced anesthesia and in drug abuse of 
phencyclidine. Concentrations of ketamine between 20 ~M and i00 ~M are 
attained during anesthesia (18). Concentrations of phencyclidine during acute 
intoxication can be as high as 2 ~JM (2). Both ketamine and phencyclidine 
characteristically activate peripheral sympathetic responses because of 
increased CNS stimulation of the peripheral sympathetic nervous systems (19). 
The inhibitory effects of ketamine and phencyclidine on nicotinic effects in 
the adrenal medulla probably moderates this increased stimulation. 
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